- Results from a preclinical study, just published in Cell Reports, underscore the importance of identifying the optimal dose of Aduro Biotech's (ADRO +2.1%) STING activator ADU-S100 in solid tumors.
- In mouse models, high doses of ADU-S100 effectively cleared injected tumors but may compromise the durability of the anti-tumor effect while lower doses demonstrated optimal CD8+ T cell responses needed for systemic and sustained anti-tumor immunity. Lower doses were also effective when combined with checkpoint inhibitor therapy.
- ADU-S100 is currently being evaluated in a Phase 1 study as monotherapy and in combination with Bristol-Myers Squibb's (BMY +2.9%) Yervoy (ipilimumab) and in a Phase 1b study with Novartis' (NVS +1.8%) anti-PD-1 antibody spartalizumab.
- Previously: Investors underwhelmed with Aduro's early-stage data on STING candidate; shares down 11% (Nov. 9)
- Now read: Affimed: Positive Takeaways From AFM-13 Focused R&D Day; Multiple Catalysts Ahead Including Potential Partnership With PD1/PD-L1 Company For AFM13 Combo Trial
Original article